Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

DUOBRII - Health Canada Drug Approval Details

Approvals/Health Canada/DUOBRII

Authorized

STANDARD

DUOBRII

bausch health, canada inc.🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: ff410c4e57b293cf
Company: bausch health, canada inc.
Type: Standard

Approval Details

Approval Id: ff410c4e57b293cf
Drug Approval Canada Name: DUOBRII
Product Name: DUOBRII
Status: Marketed
Status Date: 2020-08-04
Original Market Date: 2020-08-04
Din: 02499967
Drug Class: Human
Dosage Form: Lotion
Route Of Administration: Topical
Schedule: Prescription
Ahfs: 84:92.00
Atc Original: D05AX05 TAZAROTENE
Atc Name: d 05 ax 05
Aig Number: 0262297001
Company Name: bausch health, canada inc.
Company Address: 2150 Boul. St-Elzear Ouest, Laval, Quebec, Canada, H7L 4A8

Active Ingredients

TAZAROTENE

0.045 % / W/W

HALOBETASOL PROPIONATE

0.01 % / W/W

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

ff410c4e57b293cf

Type

Standard

Back to Health Canada Approvals